Focal Segmental Glomerulosclerosis Market
- The Focal Segmental Glomerulosclerosis Market is poised for positive growth throughout the forecast period (2023–2034) due to approval of potential drugs.
- DelveInsight's analysis indicates that US has the highest Focal Segmental Glomerulosclerosis Diagnosed Prevalence Cases, comprising 46.96% of the total in the 7MM. Following this, the Japan contributes approximately 14.83% of the diagnosed FSGS cases among the 7MM countries in 2022.
- Based on our analysis and estimations, males are predominantly more affected by Focal Segmental Glomerulosclerosis in the 7MM. This gender discrepancy may be influenced by various factors, including hormonal, genetic, or environmental considerations.
- In the 7MM, the Focal Segmental Glomerulosclerosis Market mainly consisted of Statin, Ezetimibe/Bempoidic Acid and their Combinations therapies and PCSK9i which generated nearly USD 23 million in 2022.
Request for Unlocking the Sample Page of the "Focal Segmental Glomerulosclerosis Drugs Market"
DelveInsight’s “Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology and the FSGS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Focal Segmental Glomerulosclerosis Drugs Market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM FSGS market size from 2020 to 2034. The report also covers current Focal Segmental Glomerulosclerosis Treatment Market practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Focal Segmental Glomerulosclerosis Treatment Market.
Study Period | 2020 to 2034 |
Forecast Period | 2024-2034 |
Geographies Covered |
|
Focal Segmental Glomerulosclerosis Drugs Market |
|
Focal Segmental Glomerulosclerosis Market Size | |
Focal Segmental Glomerulosclerosis Companies |
|
Focal Segmental Glomerulosclerosis Treatment Market
Focal Segmental Glomerulosclerosis is a medical condition that describes a pattern of kidney disease defined by sclerosis (scarring) in particular segments (focal) of the kidney's glomeruli, which are its filtering units. Urine is formed by the glomeruli's vital function of filtering waste and extra fluid from the blood. Symptoms of FSGS include Proteinuria (Large amounts of protein “spilling” into the urine), Edema (Swelling in parts of the body, most noticeable around the eyes, hands, feet, and abdomen, which causes sudden weight gain), Low-blood Albumin Levels, High cholesterol in some cases, high blood pressure, increased tendency to form blood clots.
Focal Segmental Glomerulosclerosis Diagnosis
In order to diagnose FSGS, a comprehensive clinical evaluation that includes a physical examination and medical history is required. Serum creatinine measurement and urinalysis are two urine and blood tests used to evaluate kidney function. Imaging tests such as CT or ultrasound scans provide information on kidney anatomy. A kidney biopsy, when required, offers a conclusive diagnosis by performing a microscopical examination of the tissue to confirm FSGS and identify its particular subtype, thereby directing suitable treatment approaches.
Focal Segmental Glomerulosclerosis Treatment
PCI and CABG are two invasive procedures used in the treatment of FSGS. The cornerstone of FSGS prevention is thought to be statins. With the hazards of statins, there are many additional therapy choices accessible, such as apolipoprotein (A) inhibitors, ezetimibe, PCSK9 inhibitors, and omega-3 fatty acids.
Focal Segmental Glomerulosclerosis Epidemiology
As the market is derived using the patient-based model, the Focal Segmental Glomerulosclerosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Focal Segmental Glomerulosclerosis Diagnosed Prevalent Cases, Focal Segmental Glomerulosclerosis Gender-specific Diagnosed Prevalent Cases, Focal Segmental Glomerulosclerosis Age-specific Diagnosed Prevalent Cases, and Focal Segmental Glomerulosclerosis Comorbodity-specific Diagnosed Prevalent Cases in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.
As per DelveInsight’s estimations, the total diagnosed prevalent cases of FSGS in the 7MM were approximately 55 million in 2022 and are projected to increase during the forecast period.
- The overall count of individuals diagnosed with Focal Segmental Glomerulosclerosis in the United States was approximately 26 million in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
- Among the 7MM, Japan accounted for the highest number of Focal Segmental Glomerulosclerosis diagnosed cases of around 8 million cases in 2022. Forecasts indicate a projected increase in the cases during the period (2023-2034).
- Among EU4 and the UK, Germany had the highest Focal Segmental Glomerulosclerosis diagnosed prevalent population, with about 5 million cases, followed by France and Italy in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
- In 2022, DelveInsight's analysis of Focal Segmental Glomerulosclerosis gender-specific diagnosed prevalent cases within the 7MM indicated an approximate distribution of 40% in males and 60% in females.
Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Focal Segmental Glomerulosclerosis Prevalence
Focal Segmental Glomerulosclerosi Recent Developments
- In May 2025, Travere Therapeutics announced that the FDA accepted its sNDA for FILSPARI (sparsentan) for focal segmental glomerulosclerosis (FSGS), with a PDUFA target date of January 13, 2026. An advisory committee meeting is also planned.
Focal Segmental Glomerulosclerosis Drug Chapters
The drug chapter segment of the Focal Segmental Glomerulosclerosis Drugs Market Report encloses a detailed analysis of Focal Segmental Glomerulosclerosis marketed drugs and late-stage (Phase III and Phase II) Focal Segmental Glomerulosclerosis pipeline drugs analysis. It also understands Focal Segmental Glomerulosclerosis clinical trials details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest Focal Segmental Glomerulosclerosis news and press releases.
Focal Segmental Glomerulosclerosis Marketed Drugs
- LEQVIO (Inclisiran): Novartis Pharmaceuticals Corporation
LEQVIO (Inclisiran) is a sole small-interfering RNA (siRNA) therapy designed to lower LDL cholesterol. The drug utilizes the RNA interference mechanism and directs the catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation. LEQVIO, the sole approved FSGS treatment in United States and Europe with an active patent, dominates the FSGS treatment landscape, immune to biosimilar competition.
Get More Insights of the Report @ INCLISIRAN Market
Focal Segmental Glomerulosclerosis Emerging Drugs
- Olpasiran (AMG 890): Amgen Inc.
Olpasiran (AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a). It is being investigated for treating FSGS; the drug is administered subcutaneously as a solution. Olpasiran is currently in Phase III clinical trial in participants with FSGS and elevated lipoprotein (a).
The absence of approved alternatives highlights the potential for Olpasiran to contribute significantly to the expansion of the FSGS treatment market.
See More Insights of the Report @ OLPASIRAN Market
Focal Segmental Glomerulosclerosis Market Outlook
Focal Segmental Glomerulosclerosis (FSGS), encompassing diverse conditions like CAD, PAD, and cerebrovascular disease, all rooted in atherosclerosis. FSGS is influenced by genetic predisposition, lifestyle factors, and comorbidities. Strategies vary depending on the severity of the disease, aiming to curb FSGS. Treatment for FSGS starts with a change in lifestyle that includes stress management, regular exercise, dietary adjustments, and quitting smoking. Their potential to supplement pharmaceutical therapies and effectively lower cardiovascular risk factors is highlighted by a thorough examination of their influence on patient outcomes.
As the Focal Segmental Glomerulosclerosis Treatment Market Landscape evolves, the emergence of Olpasiran in a Phase III trial brings hope for a targeted therapeutic option. The projected introduction of Olpasiran for FSGS is anticipated to propel the overall FSGS market in the 7MM, potentially reaching nearly USD 837 million by 2034.
- The Focal Segmental Glomerulosclerosis Market Size in the 7MM reached approximately USD 734 million in 2022. Projections indicate a steady growth during the forecast period.
- Out of the 7MM, Japan dominated the Focal Segmental Glomerulosclerosis Drugs Market in 2022, representing the largest share at nearly 46%.
- The US alone represented approximately 34% of the total Focal Segmental Glomerulosclerosis Drugs Market in 2022, projected to increase at a substantial CAGR during the study period.
- In 2022, EU4 and the UK captured an estimated USD 147 million, which is anticipated to increase at a substantial CAGR. Among the European countries, France covered the largest market share in 2022, followed by Germany.
- At present, the Focal Segmental Glomerulosclerosis Pipeline is limited. Nevertheless, with increased awareness and extensive research, the market outlook for Focal Segmental Glomerulosclerosis treatment indicates a gradual expansion, promising a future characterized by effective management protocols.
Focal Segmental Glomerulosclerosis Drugs Uptake
This section focuses on the uptake rate of potential Focal Segmental Glomerulosclerosis drugs expected to launch in the market during 2020–2034. For example, Olpasiran (AMG 890), in the US is expected to get launched by 2028 with 7 Peak year.
Focal Segmental Glomerulosclerosis Pipeline Drugs Analysis
The Focal Segmental Glomerulosclerosis therapeutics market report provides insights into different therapeutic candidates in late phase, mid-phase and early phase stage. It also analyzes key Focal Segmental Glomerulosclerosis companies involved in developing targeted therapeutics.
Focal Segmental Glomerulosclerosis Pipeline Development Activities
The Focal Segmental Glomerulosclerosis treatment market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for FSGS emerging therapies.
Take Your Research to the Next Level! Click Here to Get Access to the Full Focal Segmental Glomerulosclerosis Pipeline Drugs Analysis Report @ Focal Segmental Glomerulosclerosis Treatment Drugs
KOL Views
To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on FSGS evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Yale School of Medicine, Yale University, United States;; Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany; Cardiovascular Prevention Institute, Paris, France; University Hospital Ramón y Cajal, Madrid, Spain; Maria Cecilia Hospital, GVM Care & Research, Lugo, Italy; University of Manchester, England, UK; Department of Cardiology, Kawasaki Medical School, Kurashiki, Japan; and others.
Delveinsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or FSGS market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Focal Segmental Glomerulosclerosis unmet needs.
Focal Segmental Glomerulosclerosis Drugs Market: Qualitative Analysis
We perform Qualitative and market intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, Focal Segmental Glomerulosclerosis Competitive Analysis landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Focal Segmental Glomerulosclerosis Therapeutics Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. The Focal Segmental Glomerulosclerosis therapeutics market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Focal Segmental Glomerulosclerosis Therapeutics Market Report Scope
- The Focal Segmental Glomerulosclerosis Therapeutics Market Report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the Focal Segmental Glomerulosclerosis epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
- Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
- A detailed review of the Focal Segmental Glomerulosclerosis Therapeutics Market, historical and forecasted Focal Segmental Glomerulosclerosis Treatment Market Size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
- The patient-based Focal Segmental Glomerulosclerosis Market forecasting report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Focal Segmental Glomerulosclerosis Therapeutics Market.
Focal Segmental Glomerulosclerosis Therapeutics Market Report Insights
- Patient-based Focal Segmental Glomerulosclerosis Market Forecasting
- Focal Segmental Glomerulosclerosis Therapeutic Approaches
- Focal Segmental Glomerulosclerosis Pipeline Drugs Analysis
- Focal Segmental Glomerulosclerosis Market Size
- Focal Segmental Glomerulosclerosis Market Trends
- Existing and Future Focal Segmental Glomerulosclerosis Therapeutics Market Opportunity
Focal Segmental Glomerulosclerosis Therapeutcs Market Report Key Strengths
- 12 years Focal Segmental Glomerulosclerosis Market Forecast
- The 7MM Coverage
- Focal Segmental Glomerulosclerosis Epidemiology Segmentation
- Key Cross Competition
- Conjoint Analysis
- Focal Segmental Glomerulosclerosis Drugs Uptake
- Key Focal Segmental Glomerulosclerosis Market Forecast Assumptions
Focal Segmental Glomerulosclerosis Therapeutics Market Report Assessment
- Current Focal Segmental Glomerulosclerosis Treatment Market Practices
- Focal Segmental Glomerulosclerosis Unmet Needs
- Focal Segmental Glomerulosclerosis Pipeline Drugs Analysis
- Focal Segmental Glomerulosclerosis Therapeutics Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
Key Questions
Focal Segmental Glomerulosclerosis Treatment Market Insights
- What was the Focal Segmental Glomerulosclerosis Market Size, the Focal Segmental Glomerulosclerosis treatment market size by therapies, and Focal Segmental Glomerulosclerosis market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?
- What unmet needs are associated with the current treatment market of FSGS?
- What are the patents of emerging therapies for FSGS?
- Which drug is going to be the largest contributor by 2034?
- What are the pricing variations among different geographies for approved and off-label therapies?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Focal Segmental Glomerulosclerosis Epidemiology Insights
- What are the disease risks, burdens, and Focal Segmental Glomerulosclerosis unmet needs? What will be the growth opportunities across the 7MM concerning the patient population of FSGS?
- What is the historical and forecasted FSGS patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
- Why do only limited patients appear for diagnosis?
- Which country is more prevalent for FSGS and why?
- What factors are affecting the diagnosis of the indication?
Current Focal Segmental Glomerulosclerosis Treatment Market Scenario, Marketed Drugs, and Emerging Therapies
- What are the current options for treating Focal Segmental Glomerulosclerosis? What are the current guidelines for treating Focal Segmental Glomerulosclerosisin the US and Europe?
- How many Focal Segmental Glomerulosclerosis companies are developing therapies for treating Focal Segmental Glomerulosclerosis?
- How many emerging therapies are in the mid-stage and late stage of development for treating Focal Segmental Glomerulosclerosis?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
- What are the key designations that have been granted for the emerging therapies for Focal Segmental Glomerulosclerosis?
- Patient acceptability in terms of preferred treatment options as per real-world scenarios?
- What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
- What are the 7MM historical and forecasted Focal Segmental Glomerulosclerosis Drugs Market?
Reasons to Buy
- The Focal Segmental Glomerulosclerosis Treatment Market Report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the FSGS Drugs Market.
- Insights on patient burden/disease Focal Segmental Glomerulosclerosis Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the existing Focal Segmental Glomerulosclerosis Drugs Market opportunity in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
- Identifying strong upcoming Focal Segmental Glomerulosclerosis Companies in the market will help devise strategies that will help get ahead of competitors.
- Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
- To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet needs of the existing Focal Segmental Glomerulosclerosis Drugs Market so that the upcoming players can strengthen their development and launch strategy.
Read Our Recent Articles